Structured self-management improved HbA1c and blood pressure, but not albuminuria, in people at risk of diabetic kidney disease

Design

Single-centre, two-arm randomised controlled trial

Population

134 adults with type 2 diabetes at high predicted risk of diabetic kidney disease, China

Primary outcome

HbA1c, UACR, eGFR, SBP, LDL-C, BMI and waist at 12 and 24 weeks

Effect

Improved HbA1c, eGFR, SBP and LDL-C; no difference in UACR, BMI or waist

A single-centre randomised trial at a tertiary hospital in Shandong, China, enrolled 134 people with type 2 diabetes classed as high risk for diabetic kidney disease by a validated prediction model. Half received a 12-week structured self-management programme followed by 12 weeks of follow-up; half had usual care.

The intervention group improved more on HbA1c, eGFR, systolic blood pressure and LDL cholesterol. There was no difference in the urine albumin-to-creatinine ratio, body mass index or waist circumference. The abstract reports these as significant differences without giving the size of each change, so how large the benefit was cannot be judged from what is available.

The pattern is plausible: self-management moves the risk factors that respond to adherence and monitoring. Albuminuria, the earliest marker of kidney damage, did not shift over 24 weeks. The trial is small, short and unblinded by nature, and the eGFR change over six months should be read cautiously.

• Structured self-management education is worth offering early, before kidney disease is established, not only after albuminuria appears.
• Track urine albumin-to-creatinine ratio separately: it did not improve with education alone in this trial.
• Programmes that target glucose, blood pressure and lipids together are more likely to move all three than single-target advice.
• Education is an addition to SGLT2 inhibitors and renin–angiotensin blockade where indicated, not a substitute.

Why it matters

The markers that moved were the modifiable risk factors; the kidney marker that defines early disease did not.

Don't overread it

A six-month eGFR difference in a small single-centre trial is not evidence of slowed kidney disease.

The statistics, in plain English

The trial reports statistically significant differences without effect sizes in its abstract, so we cannot say whether the improvements were clinically meaningful. With 134 people over 24 weeks, a short-term eGFR change can reflect haemodynamic shifts rather than protected kidney function.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.